Anti Cardiolipin IgM
- UID
- MFG/MD/2018/000022_9f8f66b04f3280cc72a8688a3aa3ddf4_b4014450c9a8ddfd15fc20c932332326
- Device class
- Class B
- Brand name
- Merilisa
- License holder
- Meril Diagnostics Pvt. Ltd.
- Approving authority
- Gujarat
- Product information
- Anti Cardiolipin IgM is an indirect solid phase immunoassay kit for the quantitative measurement of IgM class autoantibodies directed against Cardiolipina-β2-glycoprotein complex in human serum or plasma. The assay is intended for in vitro diagnostic use only as an aid in the diagnosis of increased risk of thrombosis in patients with Systemic Lupus Eritematosus (Merilisa) or similar disorders. Anti Cardiolipin IgM kit is intended for laboratory use only
Anti Cardiolipin IgM is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID MFG/MD/2018/000022_9f8f66b04f3280cc72a8688a3aa3ddf4_b4014450c9a8ddfd15fc20c932332326. This device is marketed under the brand name Merilisa. The license holder is Meril Diagnostics Pvt. Ltd., and it is classified as Device Class Class B. The approving authority is Gujarat.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.